Program Code: SCF-DBI-PCICU-MYO-0001**
Operational Window: Initial Presentation → Rescue Phase → Recovery Phase → Longitudinal Surveillance
Primary Objective: Preserve myocardial biological intelligence, prevent neurocardiac collapse, protect end-organ function, support myocardial recovery, and optimize long-term cardiovascular adaptation.
SECTION 6.1
CLINICAL POSITIONING
Traditional Heart Failure Model
Focuses on:
Ventricular function
Cardiac output
Ejection fraction
Hemodynamic support
Survival
SCF-DBI Myocardial Intelligence Model
Myocardial disease is viewed as:
Neuroimmune-Neurocardiac Adaptation Failure Syndrome
affecting:
Myocardial contractility
Endothelial adaptation
Cerebral perfusion
Metabolic resilience
Recovery intelligence
Core Principle
The primary goal is preservation of myocardial recovery potential before irreversible remodeling occurs.
SECTION 6.2
PEDIATRIC MYOCARDITIS SOP
Clinical Positioning
Myocarditis is viewed as:
Immune-Mediated Myocardial Intelligence Injury Syndrome
Primary Mechanisms
Direct inflammatory injury
Immune-mediated injury
Electrical instability
Contractile dysfunction
Neuroimmune dysregulation
Clinical Presentations
Mild myocarditis
Acute myocarditis
Fulminant myocarditis
Chronic inflammatory cardiomyopathy
SECTION 6.3
MYOCARDITIS BIOLOGICAL INTELLIGENCE MODEL
Phase 1
Immune Activation
Characteristics:
Viral or immune trigger
Neuroimmune activation
Cytokine signaling
Phase 2
Myocardial Injury
Characteristics:
Troponin elevation
Ventricular dysfunction
Arrhythmias
Phase 3
Adaptation Failure
Characteristics:
Reduced output
Endothelial stress
Perfusion abnormalities
Phase 4
Recovery or Remodeling
Outcomes:
Full recovery
Partial recovery
Progressive cardiomyopathy
SECTION 6.4
FULMINANT MYOCARDITIS RESCUE PROGRAM
Clinical Positioning
Fulminant myocarditis represents:
Acute Neurocardiac Collapse Syndrome
Immediate Threats
Cardiogenic shock
Ventricular arrhythmias
Multi-organ dysfunction
Cardiac arrest
Initial Objectives
Stabilize perfusion
Preserve myocardium
Preserve cerebral oxygenation
Support recovery potential
Monitoring Variables
Troponin
BNP
Lactate
NIRS
ANMS
NCRS
SECTION 6.5
PEDIATRIC CARDIOMYOPATHY SOP
Disease Categories
Dilated Cardiomyopathy
Hypertrophic Cardiomyopathy
Restrictive Cardiomyopathy
Arrhythmogenic Cardiomyopathy
Mixed Phenotypes
SCF Positioning
Cardiomyopathy represents:
Chronic Neurocardiac Adaptation Failure
with progressive loss of:
Functional reserve
Recovery reserve
Growth reserve
SECTION 6.6
ACUTE DECOMPENSATED HEART FAILURE PATHWAY
Strategic Goals
Restore:
Cardiac output
Oxygen delivery
End-organ perfusion
Recovery reserve
Surveillance Variables
Echocardiography
BNP
Troponin
Lactate
Mixed venous oxygen saturation
NIRS
Heart Failure Severity Staging
Stage I
Compensated
Stage II
Progressive
Stage III
Decompensated
Stage IV
Critical
SECTION 6.7
NEUROIMMUNE CARDIAC INJURY FRAMEWORK
Strategic Position
Many pediatric cardiac diseases involve:
Neuroimmune activation
Endothelial injury
Myocardial stress
Recovery disruption
Monitoring Domains
Immune Activation
CRP
Ferritin
Cytokines
Myocardial Injury
Troponin
BNP
Echocardiography
Recovery Status
STRI
ANMS
NCRS
SECTION 6.8
RHENOVA MYOCARDIAL RECOVERY PLATFORM
Strategic Objective
Promote myocardial recovery while preventing adverse remodeling.
Recovery Domain 1
Contractile Recovery
Recovery Domain 2
Electrical Recovery
Recovery Domain 3
Endothelial Recovery
Recovery Domain 4
Metabolic Recovery
Recovery Domain 5
Functional Recovery
SECTION 6.9
MECHANICAL CIRCULATORY SUPPORT (VAD) SOP
Clinical Positioning
VAD support is viewed as:
Myocardial Recovery Preservation Technology
Indications
Refractory heart failure
Progressive cardiomyopathy
Fulminant myocarditis
Bridge-to-transplant
Bridge-to-recovery
Objectives
Restore systemic perfusion
Reduce myocardial workload
Preserve organ viability
Enable recovery
Monitoring Variables
Device flow
Ventricular unloading
Lactate
NIRS
NCRS
SECTION 6.10
ECMO VS VAD DECISION FRAMEWORK
ECMO Preferred When
Acute collapse
Severe hypoxemia
Severe circulatory failure
Cardiac arrest recovery
VAD Preferred When
Chronic heart failure
Isolated cardiac dysfunction
Extended bridge support
Recovery optimization
SCF Goal
Select the platform that best preserves biologic intelligence and recovery potential.
SECTION 6.11
CARDIAC TRANSPLANT BRIDGE-TO-RECOVERY ALGORITHMS
Candidate Categories
Fulminant myocarditis
Advanced cardiomyopathy
Refractory heart failure
Pathway A
Recovery Expected
↓
Mechanical support
↓
Myocardial recovery
↓
Support removal
Pathway B
Recovery Uncertain
↓
Mechanical support
↓
Reassessment
↓
Transplant evaluation
Pathway C
Recovery Unlikely
↓
Mechanical support
↓
Transplant listing
↓
Transplantation
SECTION 6.12
MYOCARDIAL RECOVERY INTELLIGENCE SURVEILLANCE
Domain A
Contractility
Monitor:
Ventricular function
Cardiac output
Domain B
Electrical Stability
Monitor:
Rhythm burden
Conduction stability
Domain C
Recovery Biology
Monitor:
ANMS
NCRS
STRI
EII
Output
Myocardial Recovery Index (MRI)
SECTION 6.13
ESCALATION MATRIX
Level 1
Enhanced Monitoring
Triggers:
Troponin increase
BNP increase
Level 2
Focused Intervention
Triggers:
Lactate increase
NCRS decline >15%
Level 3
Multidisciplinary Escalation
Triggers:
Progressive ventricular dysfunction
Arrhythmias
EII decline >20%
Level 4
Mechanical Support Consideration
Triggers:
Severe heart failure
Cardiogenic shock
Level 5
Cardiac Rescue Activation
Triggers:
ANMS <40
Progressive MODS
Circulatory collapse
SECTION 6.14
LONGITUDINAL MYOCARDIAL RECOVERY PROGRAM
Follow-Up Windows
Discharge
↓
30 Days
↓
90 Days
↓
6 Months
↓
12 Months
↓
Annual Review
Recovery Domains
Cardiac function
Exercise tolerance
Neurodevelopment
Growth
Quality of life
SECTION 6.15
MYOCARDIAL RECOVERY ENDPOINTS
Clinical
Stable ventricular function
Stable rhythm
Reduced hospitalization
Functional
Exercise participation
Age-appropriate development
Educational participation
Biological Intelligence
ANMS >80
NCRS >80
STRI >80
EII >80
Myocardial Recovery Index optimized
PAGE 6 COMPLETION
Next Page (Page 7):